- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02123329
Assessing the Effectiveness of a Pharmacist-delivered Smoking Cessation Program in the State of Qatar
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Doha, Qatar
- Primary Health Corporation (PHC) pharmacies
-
Doha, Qatar
- Qatar Petroleum pharmacies
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Eligible participants are:
- patients aged 18 years and older who currently smoke one or more cigarettes daily for 7 days, are motivated to quit i.e.: in the preparation stage of the stage-of-change model, able to communicate in Arabic or English and are willing and capable of attending the scheduled sessions at the study pharmacies.
Exclusion criteria are:
- use of other nicotine or tobacco products
- current use or use in the last 30 days of quit smoking aids or medications
- plan to leave Qatar in the next 12 months
- presence of any major medical condition that would prevent use of the nicotine replacement therapy including hypersensitivity to the products, history of or recent myocardial infarction, life-threatening arrhythmias, severe or worsening angina, uncontrolled hypertension and temporomandibular joint disease (in case of nicotine gum)
- pregnancy
- psychiatric illness or other debilitating condition that would interfere with participation in the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Control arm
Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist.
In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
|
Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist.
In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
|
Experimentell: Intervention arm
Participants assigned to the intervention arm will participate in a face-to-face 4-session program at the pharmacy delivered by the study pharmacist at 2-4-week intervals over 8 weeks in addition to nicotine replacement therapy.
The sessions will be set at a date and time that is convenient for both the pharmacist and the participant.
The pharmacist will deliver the program at a time different from his or her pharmacy duty regular time.
|
The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies. To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability. • If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Self-reported 7-day Point Prevalence Abstinence
Tidsram: 3 months
|
Self-reported 7-day point prevalence abstinence, defined as having smoked no cigarettes for the previous 7 days
|
3 months
|
Self-reported 30 Day Smoking Abstinence
Tidsram: 3 months
|
Self-reported 30-day point prevalence abstinence defined as having smoked no cigarettes in the last 30 days
|
3 months
|
Self-reported Continuous Abstinence at 3 Months
Tidsram: 3 months
|
Self-reported continuous abstinence defined as having smoked no cigarettes since quit day
|
3 months
|
Self-reported 7-day Point Prevalence Abstinence
Tidsram: 6 months
|
Defined as having smoked no cigarettes for the previous 7 days
|
6 months
|
Self-reported 30-day Point Prevalence Abstinence
Tidsram: 6 months
|
Defined as having smoked no cigarettes in the last 30 days
|
6 months
|
Self-reported Continuous Abstinence
Tidsram: 6 months
|
Defined as having smoked no cigarettes since quit day
|
6 months
|
Self-reported 7-day Point Prevalence Abstinence
Tidsram: 12 months
|
Defined as having smoked no cigarettes for the previous 7 days
|
12 months
|
Self-reported 30-day Point Prevalence Abstinence
Tidsram: 12 months
|
Defined as having smoked no cigarettes in the last 30 days
|
12 months
|
Self-reported Continuous Abstinence
Tidsram: 12 months
|
Defined as having smoked no cigarettes since quit day at 12 months
|
12 months
|
Objective Smoking Abstinence
Tidsram: 12 months
|
Smoking abstinence as objectively verified by the CO exhaled test at 12 months
|
12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Health Related Quality of Life
Tidsram: 6 month
|
Mean change in health related quality of life score from baseline to 6 months for quitters vs. non quitters
|
6 month
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Maguy S El Hajj, PharmD, Qatar University
Publikationer och användbara länkar
Allmänna publikationer
- El Hajj MS, Kheir N, Al Mulla AM, Shami R, Fanous N, Mahfoud ZR. Effectiveness of a pharmacist-delivered smoking cessation program in the State of Qatar: a randomized controlled trial. BMC Public Health. 2017 Feb 20;17(1):215. doi: 10.1186/s12889-017-4103-4.
- El Hajj MS, Kheir N, Al Mulla AM, Al-Badriyeh D, Al Kaddour A, Mahfoud ZR, Salehi M, Fanous N. Assessing the effectiveness of a pharmacist-delivered smoking cessation program in the State of Qatar: study protocol for a randomized controlled trial. Trials. 2015 Feb 26;16:65. doi: 10.1186/s13063-015-0570-z.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- NPRP 4 - 716 - 3 - 203
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Control arm (i.e: regular care)
-
Scott and White Hospital & ClinicAvslutad
-
Rabin Medical CenterAvslutad
-
San Diego State UniversityNational Heart, Lung, and Blood Institute (NHLBI)AvslutadLungsjukdomar | TuberkulosFörenta staterna
-
Duke UniversityAvslutadFör tidig födselFörenta staterna
-
Coventry UniversityThe University of Hong Kong; Radboud University, Donders Institute for... och andra samarbetspartnersHar inte rekryterat ännuDepression | Smärta | Påfrestning | Ångest | Mentalt välbefinnande | Prosocialt beteende | Uppmärksamhet | Empati | FörlåtelseKina, Indien